Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Class R Redeemable Shares	Common Stock Class A Ordinary Shares	Common Stock Class B Ordinary Shares	Common Stock Class R Redeemable Shares	Deferred Shares	Additional Paid-In Capital	Unitholders’/ Shareholders’ Contributions	Retained Earnings	Retained Earnings Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Income	Non-Controlling Interests	Treasury Interests
Beginning balance (in shares) at Dec. 31, 2019				0	0	0	0
Beginning balance at Dec. 31, 2019	$ 6,141,438	$ (192,705)		$ 0	$ 0	$ 0	$ 0	$ 0	$ 3,282,516	$ 2,825,212	$ (192,705)	$ 2,093	$ 35,883	$ (4,266)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Contributions	1,482,322								307,646				1,174,676
Transfer of interests	0								(1,037,161)				1,037,161
Distributions	(1,105,765)									(313,408)			(792,357)
Initial share issuance upon registration of Royalty Pharma plc (in shares)						50,000
Initial share issuance upon registration of Royalty Pharma plc	63					$ 63
Net income	1,701,954
Issuance of Class B ordinary shares to continuing investors partnerships (in shares)					535,383,000
Issuance of Class B ordinary shares to Continuing Investors Partnerships	1				$ 1
Effect of exchange by continuing investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity (in shares)				294,176,000	(294,176,000)		294,176,000
Effect of exchange by Continuing Investors of Class B ordinary shares for Class A ordinary shares and reallocation of historical equity	(1)			$ 30	$ (1)			1,402,762	(2,553,001)	(1,261,014)		(24,022)	2,433,098	2,147
Issuance of Class A ordinary shares sold in IPO, net of offering costs (in shares)				71,652,000
Issuance of Class A ordinary shares sold in IPO, net of offering costs	1,908,744			$ 7				1,150,383					758,354
Share based compensation and related issuance of Class A ordinary shares (in shares)				76,000
Share-based compensation and related issuances of Class A ordinary shares	5,428							5,428
Other exchanges (in shares)				22,231,000	(22,231,000)		22,231,000
Other exchanges	191			$ 2				307,391				2,562	(309,566)	(198)
Dividends	(112,490)									(112,490)
Other comprehensive income/(loss):
Reclassification of loss on interest rate swaps	4,066											4,066
Unrealized gains on available for sale debt securities	83,120											60,617	22,503
Reclassification of unrealized gains on available for sale debt securities	(20,551)											(10,921)	(9,630)
Ending balance (in shares) at Dec. 31, 2020				388,135,000	218,976,000	50,000	316,407,000
Ending balance at Dec. 31, 2020	9,895,815			$ 39	$ 0	$ 63	$ 0	2,865,964	$ 0	1,920,635		34,395	5,077,036	(2,317)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Contributions	48,539												48,539
Distributions	(614,973)												(614,973)
Net income	1,241,201									619,728			621,473
Share based compensation and related issuance of Class A ordinary shares (in shares)				65,000
Share-based compensation and related issuances of Class A ordinary shares	2,443							2,443
Other exchanges (in shares)				44,763,000	(44,763,000)		44,763,000
Other exchanges	0			$ 4				639,126				4,242	(642,974)	(398)
Dividends	(285,184)									(285,184)
Other comprehensive income/(loss):
Reclassification of loss on interest rate swaps	0
Unrealized gains on available for sale debt securities	11,600											6,335	5,265
Reclassification of unrealized gains on available for sale debt securities	(50,896)											(28,481)	(22,415)
Ending balance (in shares) at Dec. 31, 2021				432,963,000	174,213,000	50,000	361,170,000
Ending balance at Dec. 31, 2021	10,248,545			$ 43	$ 0	$ 63	$ 0	3,507,533		2,255,179		16,491	4,471,951	(2,715)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Contributions	11,596												11,596
Distributions	(604,248)												(604,248)
Net income	230,064									42,832			187,232
Share based compensation and related issuance of Class A ordinary shares (in shares)				48,000
Share-based compensation and related issuances of Class A ordinary shares	2,170							2,170
Other exchanges (in shares)				10,155,000	(10,155,000)		10,155,000
Other exchanges	0			$ 1				156,457				1,127	(157,494)	(91)
Dividends	(333,322)									(333,322)
Other comprehensive income/(loss):
Reclassification of loss on interest rate swaps	0
Unrealized gains on available for sale debt securities	24,000											14,262	9,738
Reclassification of unrealized gains on available for sale debt securities	(53,432)											(31,880)	(21,552)
Ending balance (in shares) at Dec. 31, 2022			50,000	443,166,000	164,058,000	50,000	371,325,000
Ending balance at Dec. 31, 2022	$ 9,525,373			$ 44	$ 0	$ 63	$ 0	$ 3,666,160		$ 1,964,689		$ 0	$ 3,897,223	$ (2,806)